By Will Feuer

 

Agilent Technologies Inc. said the Food and Drug Administration has approved Teva Pharmaceutical Industries Ltd.'s content uniformity method using Agilent's TRS100 Raman quantitative pharmaceutical analysis system.

Agilent said its TRS100 system helps measure how much active pharmaceutical ingredient is inside a tablet or capsule, and whether the amount is uniform across a batch.

"It is a substantial investment to change manufacturing and QC processes, and an FDA approval minimizes the perceived risk of adopting this new technology," said Geoff Winkett, Agilent vice president of molecular spectroscopy.

The FDA's approval of the TRS100 method for content uniformity testing by Teva is a key milestone for the product, Mr. Winkett said.

 

Write to Will Feuer at Will.Feuer@wsj.com

 

(END) Dow Jones Newswires

July 05, 2022 08:41 ET (12:41 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Ago 2022 até Set 2022 Click aqui para mais gráficos Agilent Technologies.
Agilent Technologies (NYSE:A)
Gráfico Histórico do Ativo
De Set 2021 até Set 2022 Click aqui para mais gráficos Agilent Technologies.